| Diminished efficacy of programmed death-(ligand) 1 inhibition in STK11-and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status B Ricciuti, KC Arbour, JJ Lin, A Vajdi, N Vokes, L Hong, J Zhang, ... Journal of Thoracic Oncology 17 (3), 399-410, 2022 | 273 | 2022 |
| Association of high tumor mutation burden in non–small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 … B Ricciuti, X Wang, JV Alessi, H Rizvi, NR Mahadevan, YY Li, A Polio, ... JAMA oncology 8 (8), 1160-1168, 2022 | 233 | 2022 |
| Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in … JV Alessi, B Ricciuti, SL Alden, AA Bertram, JJ Lin, M Sakhi, M Nishino, ... Journal for immunotherapy of cancer 9 (11), e003536, 2021 | 81 | 2021 |
| Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced NSCLC JV Alessi, A Elkrief, B Ricciuti, X Wang, A Cortellini, VR Vaz, G Lamberti, ... Journal of Thoracic Oncology 18 (6), 731-743, 2023 | 62 | 2023 |
| Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer B Ricciuti, JV Alessi, A Elkrief, X Wang, A Cortellini, YY Li, VR Vaz, ... Annals of Oncology 33 (10), 1029-1040, 2022 | 59 | 2022 |
| Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy A Cortellini, B Ricciuti, F Facchinetti, JVM Alessi, D Venkatraman, ... Annals of Oncology 32 (11), 1391-1399, 2021 | 52 | 2021 |
| Genomic and immunophenotypic landscape of acquired resistance to PD-(L) 1 blockade in non–small-cell lung cancer B Ricciuti, G Lamberti, SR Puchala, NR Mahadevan, JR Lin, JV Alessi, ... Journal of Clinical Oncology 42 (11), 1311-1321, 2024 | 40 | 2024 |
| Axillary lymphadenopathy after coronavirus disease 2019 vaccinations in patients with thoracic malignancy: incidence, predisposing factors, and imaging characteristics M Nishino, H Hatabu, B Ricciuti, V Vaz, K Michael, MM Awad Journal of Thoracic Oncology 17 (1), 154-159, 2022 | 24 | 2022 |
| Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations A Cortellini, B Ricciuti, VR Vaz, D Soldato, JV Alessi, FG Dall’Olio, ... Journal for immunotherapy of cancer 10 (2), e004374, 2022 | 23 | 2022 |
| Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in NSCLC JV Alessi, X Wang, A Elkrief, B Ricciuti, YY Li, H Gupta, LF Spurr, H Rizvi, ... Journal of Thoracic Oncology 18 (11), 1524-1537, 2023 | 18 | 2023 |
| A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions A Cortellini, APC Barrichello, JV Alessi, B Ricciuti, VR Vaz, ... Annals of Oncology 33 (11), 1202-1204, 2022 | 17 | 2022 |
| Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer A Di Federico, SL Alden, JW Smithy, B Ricciuti, JV Alessi, X Wang, ... Annals of Oncology 35 (10), 902-913, 2024 | 9 | 2024 |
| Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors F Pecci, S Nakazawa, B Ricciuti, G Harada, JK Lee, JV Alessi, ... Cancer discovery 14 (8), 1440-1456, 2024 | 9 | 2024 |
| Powassan virus infections: a systematic review of published cases L Kakoullis, VR Vaz, D Kaur, S Kakoulli, G Panos, LH Chen, I Behlau Tropical Medicine and Infectious Disease 8 (12), 508, 2023 | 8 | 2023 |
| Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer B Ricciuti, A Elkrief, J Alessi, X Wang, Y Li, H Gupta, DM Muldoon, ... Clinical Cancer Research 29 (13), 2540-2550, 2023 | 7 | 2023 |
| 312 Three-year outcomes with first-line pembrolizumab for metastatic non–small-cell lung cancer (NSCLC) with a very high PD-L1 tumor proportion score (TPS)≥ 90% B Ricciuti, JV Alessi, S Alden, G Lamberti, V Vaz, A Barrichello, L Sholl, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 4 | 2021 |
| Activating MET kinase domain mutations define a novel molecular subtype of non–small cell lung cancer that is clinically targetable with the MET inhibitor elzovantinib (TPX-0022). F Pecci, B Ricciuti, JVM Alessi, APC Barrichello, VR Vaz, G Lamberti, ... Journal of Clinical Oncology 40 (16_suppl), 9124-9124, 2022 | 3 | 2022 |
| Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors A Di Federico, L Hong, A Elkrief, R Thummalapalli, AJ Cooper, B Ricciuti, ... Annals of Oncology, 2024 | 2 | 2024 |
| Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: Tumor response dynamics as a marker for survival M Nishino, X Wang, B Ricciuti, SC Tseng, H Park, JV Alessi, VR Vaz, ... European radiology 33 (10), 7284-7293, 2023 | 1 | 2023 |
| 451 Serum albumin predicts outcome in patients with extensive stage small-cell Lung cancer (ES-SCLC) receiving first-line combination of PD-(L) 1 inhibitors and platinum … G Lamberti, B Ricciuti, V Vaz, JV Alessi, F Pecci, A Di Federico, M Awad Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 1 | 2022 |
